Ovarian failure following cytotoxic therapy

Area of Science:

• Oncology
• Reproductive Endocrinology

Background:

• Cytotoxic chemotherapy is a cornerstone in treating malignant diseases.
• Premenopausal women undergoing chemotherapy are at risk for ovarian dysfunction.
• Ovarian failure can significantly impact quality of life and long-term health.

Purpose of the Study:

• To investigate the incidence and characteristics of chemotherapy-induced ovarian failure (CIOF) in premenopausal women.
• To evaluate the effectiveness of hormone replacement therapy (HRT) in managing CIOF symptoms.

Main Methods:

• Prospective study of 18 premenopausal women treated with cytotoxic drugs for malignancy.
• Clinical assessment for symptoms and signs of ovarian failure.
• Administration of estrogen/progesterone replacement therapy to symptomatic patients.

Main Results:

• Ten out of 18 women (56%) showed evidence of ovarian failure.
• Ovarian failure was more common in women over 25 and those on continuous low-dose alkylating agents (e.g., busulphan).
• Eight women received hormone replacement therapy and counseling, reporting significant benefits.

Conclusions:

• Chemotherapy-induced ovarian failure is a common complication in premenopausal women.
• Early identification and prompt treatment with hormone replacement therapy are crucial for improving patient well-being.
• HRT should be considered even in patients with short life expectancy, provided tumor activation is not a concern.